Monthly Prescribing Reference

FDA Approves Dupixent 200mg Single-Dose Prefilled Pen

The new 200mg single-dose prefilled pen features a hidden needle and single-press auto-injection, along with visual and audio feedback to help with administration. The Food and Drug Administration ...

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...
Monthly Prescribing Reference

FDA Approval Allows for Use of Dupixent Prefilled Pens in Younger Patients

Dupixent single-dose prefilled pens feature a hidden needle and single-press auto-injection. The Food and Drug Administration (FDA) has expanded the approval of the Dupixent ® (dupilumab) single-dose ...
Nasdaq

FDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration

Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent 300 mg pre-filled pen expected to be available third quarter of 2020 ...

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Seeking Alpha

Dupixent® (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...